News
Health on MSN4h
This New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback